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ABSTRACT
In the 20 years since the National Marrow Donor Program (NMDP) facilitated the first unrelated donor trans-
plant, the organization has grown to include almost 7 million donors, and has facilitated over 30,000 transplants
on 6 continents. This remarkable accomplishment has been facilitated by the efforts of over 600 employees, and
an extensive international network including 171 transplant centers, 73 donor centers, 24 cord blood banks, 97
bone marrow collection centers, 91 apheresis centers, 26 HLA typing laboratories, and 26 Cooperative Regis-
tries. In this article, we review the history of theNMDP, and cite themajor trends in patient demographics, graft
sources, and conditioning regimens over the last 20 years.
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In 1986, when the National Marrow Donor
Program (NMDP) was established, Ronald Reagan
was President of the United States, the Big Easy was
the most popular movie, and the U.S. Supreme Court
ruled that Rotary Clubs must admit women. In
science, the first heart and lung transplant was
performed, and Prozac and AZT were first approved
for use.
The NMDP was established in July 1986 when it
was awarded a contract with the U.S. Navy to establish
the National Bone Marrow Donor Registry. The
program had 1 full-time employee and subcontracted
the information system to the University of Minne-
sota. Computer programs were DOS-based programs.
The first search requests for donors were processed in
September 1987, and the first transplant was facilitated2in December 1987. Forty-four donor centers and 7
transplant and collection centers comprised the
network. In June 1988, the Board of Directors voted
to name the organization the National Marrow Donor
Program.
Today, the program is supported in part through
multiple federal contracts administered by the Health
Resources and Services Administration (HRSA). The
NMDP employs over 600 people and the program
enjoys 160,000 square feet of office space near down-
town Minneapolis.
The NMDP is comprised of the coordinating
center in Minneapolis, 128 U.S. transplant centers,
43 international transplant centers, 66 U.S. donor
centers, and 7 international donor centers. A cord
blood program was begun in 1998 and now includes
21 U.S. cord blood banks and 3 international cord
NMDP Overview 3blood banks. In addition, the NMDP’s extensive net-
work includes 26 Cooperative International Registries
located on 6 continents. Approximately 35% of the
NMDP-facilitated transplants are performed interna-
tionally.
TRANSPLANT ACTIVITY
Over the past 20 years there have been several
major trends in transplant activity. In addition to an
increase in the overall number of adult and pediatric
transplants, there has been a dramatic increase
in transplants for patients over the age of 50 years, in
the use of reduced-intensity (RIC) preparative regi-
mens, and in the use of peripheral blood stem cells
(PBSC) and, most recently, umbilical cord blood
(UCB) as the graft source. There have been modest
increases in the use of transplant for nonmalignant dis-
eases. This section will explore these trends, as well as
highlight the changing demographics of the NMDP
transplant and donor population.
Figure 1 outlines the number of adult transplants
between 1987 and 2007. In 1988, 54 transplants were
performed; in 1997, 879 transplants were performed;
and in 2007, 2640 adult transplants were facilitated
by the NMDP. PBSC was first used as a graft source
for primary transplants in NMDP transplants in
1999, and in 2003, PBSC surpassed bone marrow
(BM) as the preferred stem cell source. Presently,
PBSC grafts comprise the majority (72%) of adult
transplants. In 2000, the NMDP facilitated its first un-
related UCB transplant for an adult patient. The num-
bers continued to grow, and by 2007 UCB was used as
a graft source in 10% of adult transplants.
Pediatric transplants have followed some similar
trends, as seen in Figure 2. As expected, there are fewer
pediatric than adult transplants. In 1987, the first pedi-
atric NMDP transplant was performed in a child with
0
200
400
600
800
1000
1200
1400
1600
1800
2000
2200
2400
2600
2800
19
87
-19
88
19
89
19
90
19
91
19
92
19
93
19
94
19
95
19
96
19
97
19
98
19
99
20
00
20
01
20
02
20
03
20
04
20
05
20
06
20
07
Year of Transplant
N
um
be
r o
f T
ra
ns
pl
an
ts
Umbilical cord blood
Peripheral blood stem cells
Bone marrow
Figure 1.Number of adult transplants facilitated by the NMDP, by
year and stem cell source.acute leukemia from Raleigh, NC. In 2007, 864 pedi-
atric unrelated transplants were performed. PBSC was
added as a graft source for primary transplants in 1999;
in 2007, 20% percent of NMDP pediatric transplants
were PBSC grafts. UCB transplants were added in
2000 for pediatric patients and in 2007 comprised
41% of pediatric unrelated transplants.
A significant trend has been an increase in the
numbers of transplants in patients over the age of 55
years. This reflects activity in the matched sibling
setting, likely because of the introduction of PBSC
grafts and RIC regimens [1,2]. This is an important ad-
vance, given the median age of 68 years for patients
with acute myelogenous leukemia (AML) [3,4].
Figure 3 outlines the number of first NMDP trans-
plants in patients over the age of 55 years. In 2000,
8% (116 of 1543 transplants) of the initial NMDP
transplants were in patients 55 years and older. By
2005, 21% (540 of 2522 transplants) of the initial
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Figure 2.Number of pediatric transplants facilitated by theNMDP,
by year and stem cell source.
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Figure 3. Initial NMDP transplants in patients 55 years of age and
older.
4 K. K. Ballen et al.NMDP transplants were in recipients over the age of
55 years. Nearly 700 transplants were performed in
patients 55 years and older in 2006; over 400 of these
were RIC approaches. Less toxic conditioning regi-
mens, the use of PBSC grafts, improvement in sup-
portive care, and optimal patient and donor selection
have allowed older patients to receive unrelated trans-
plants with some success.
With the introduction of RIC preparative regi-
mens and better supportive care, NMDP transplants
are now performed in patients over the age of 65 years,
and, rarely, in patients over the age of 70 years. The
NMDP has facilitated 461 transplants for patients
aged 65 to 69 years, and 86 transplants for patients
aged 70 years and over. Eighty-three percent of trans-
plants in the patients 65 years and older were PBSC
grafts. The most common diseases for these older
patients were AML, myelodysplasia (MDS), and
lymphoma.
Over the past 20 years, transplants have been
performed for a wider variety of diseases. The majority
of transplants are for hematologic malignancies (89%)
(predominantly leukemia and lymphoma) in both
adults and children. There has been a trend to fewer
transplants for chronic myelogeneous leukemia
(CML), with the introduction of oral tyrosine kinase
inhibitors such as imatinib. Recently, there has been
more interest in transplant for plasma cell disorders
[5]. Figures 4 and 5 demonstrate the breakdown by
disease for adults and children over time.
Severe aplastic anemia (SAA) is the most common
indication for transplantation in children among the
nonmalignant diseases. Despite the introduction of
immunosuppressive therapy, the number of trans-
plants for SAA has increased in the last 10 years
(Figure 6). In children, transplants for other nonmalig-
nant conditions included transplants for immune defi-
ciencies andmetabolic disorders. Of the 7724 pediatric
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Figure 4. Number of adult transplants for hematologic malignan-
cies.transplants facilitated by the NMDP, 530 (7%) were
for metabolic disorders, and 595 (8%) were for
immune deficiencies. The numbers of these trans-
plants have also increased considerably over time
from\20 per year before 1990 to over 300 pediatric
transplants annually for non-malignant conditions.
This trend is illustrated in Figure 6.
For adults, a significant change has been the intro-
duction of unrelated transplant for solid tumors, such
as renal cell carcinoma, based on data in the matched
sibling setting [6]. The first transplant for a solid
tumor was performed in 1994. Seventy-seven trans-
plants have been performed for solid tumors in adults
and children at 33 transplant centers. In addition,
unrelated transplants are now occasionally performed
for autoimmune disease.
The number of unrelated transplants for SAA in
adults has risen sharply over the last 20 years, with 3
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Figure 5. Number of pediatric transplants for hematologic malig-
nancies.
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Figure 6. Number of pediatric transplants for nonmalignant dis-
eases.
NMDP Overview 5in 1988 and 85 in 2007. Although triple-drug immuno-
suppressive therapy was introduced as a viable treat-
ment for SAA in 1991, unrelated bone marrow
transplantation remains an attractive choice for young
patients with SAA, or for those patients who fail immu-
nosuppressive therapy [7-9]. These trends are
illustrated in Figure 7.
The racial and ethnic composition of the United
States has changed in the last 20 years. Census data in-
dicates that in 2000, 69% of Americans we Caucasian.
The diversity of both the donor and the recipient
pool of the NMDP have changed accordingly [10,11].
Donor issues will be addressed in the chapter on donor
activity. In 2007, 552 transplants (16%) were per-
formed in non-Caucasians. These transplants include
172 (5%) in African Americans, 238 (7%) inHispanics,
92 (3%) in Asian/Pacific Islanders, and 11 (0.3%) in
Native Americans (Figure 8). Although numerous ad-
vances in donor recruitment and patient access have
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Figure 7. Number of adult transplants for severe aplastic anemia.been made, the number of African American unrelated
transplant recipients in the United States is underrep-
resented compared to the population as a whole (12%
in census 2000 data, 5% of transplant recipients from
2003 to 2007). Ethnically diverse donor recruitment
and patient access to transplantation remain challenges
that the NMDP is actively addressing, in the following
section.
As stated above, a major advance over the last 20
years is the ability to transplant older patients success-
fully. This advance is because of, in large part, the
introduction of non-myeloablative or RIC preparative
regimens. First pioneered in the related donor setting,
these regimens are immunosuppressive, not myeloa-
blative, and better tolerated by patients in terms of
organ function, mucositis, and risk of infection
[12-14]. Starting in 1999, these RIC transplants have
had exponential growth. In 1997, 8% of transplants
were reduced-intensity. Presently, reduced-intensity
approaches are utilized in approximately half of
NMDP-facilitated transplants. Definitions of a non-
ablative or RIC transplant differ widely; current Cen-
ter for International Blood and Marrow Transplant
Research (CIBMTR) guidelines define regimens with
.800 cGy total body radiation (TBI) and .150 mg/
m2 melphalan as myeloablative [15].
Results of the first 285 RIC transplants facilitated
by the NMDP were recently reported by Giralt et al.
[15]. Patients who received RIC unrelated transplants
were older (median 55 years versus 33 years) and had
more advanced disease (81% versus 51%) than recipi-
ents of myeloablative transplants. The 5-year survival
rate was 23%. As expected, patients who were young,
with a good performance status, earlier disease stage,
and a fully matched donor did best. Further outcome
data on RIC transplants will be presented in this issue
of the Journal.U.S. Population
Census 2000
Hispanic
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Transplant Recipients
1993–1997
Hispanic
6%
Mult/Oth
1%
API
3%
Native
0.3%
Caucasian
85%
Dec/Unk
1%
Black
4%
Figure 8. Comparison between transplant recipient population and U.S. population. Black 5 Black/African American; API 5 Asian/Pacific
Islander; Native 5 American Indian/Alaska Native; Mult/Oth 5 multiple race/other race; Dec/Unk 5 declined/unknown.
6 K. K. Ballen et al.CONTRIBUTIONS OF THE NMDP
The contributions of the NMDP in the last 20
years transcend the transplant numbers illustrated
above. The program has had extensive influence on
the transplant community in areas such as education
on unrelated hematopoietic cell transplantation
(HSCT), donor and patient safety; information sys-
tems, including sophisticatedmatching algorithms; ac-
cess to transplantation; patient and donor advocacy;
and clinical research activity, most notably with eluci-
dating the level of histocompatibility required between
patient and donor for successful outcome.
Since 1987, the NMDP has brought its network of
centers together at the annual Council Meeting, a dy-
namic educational event where attendees gain essential
training and education on advances in unrelated hema-
topoietic cell transplantation. Today, the Council
Meeting attracts nearly 1000 attendees from over 35
countries. In addition to the annual Council Meeting,
theNMDPprovides extensive training to new network
staff and ongoing training for existing staff through in-
person training sessions and Web-based training
events.
Donor and patient safety is of paramount impor-
tance to theNMDP. TheNMDP has established stan-
dards that govern criteria for participating centers,
recruitment of adult and cord blood donors, medical
evaluation of donors, and the collection, transporta-
tion, processing, and labeling of hematopoietic cells.
These standards specify, for example, required donor
testing for infectious diseases, the maximum harvest
volumes for BM donors and post-donation follow-up
for BM and PBSC donors. In addition, the NMDP
has developed guidelines that contribute to donor
safety. These include calcium replacement guidelines
for PBSC donors and guidelines on the number of
times a donor may be requested for subsequent dona-
tions for the same recipient. Many institutions have
adapted these safety parameters for their related
donors as well. The NMDP Donor and Patient Safety
Monitoring Committeemeets 4 times a year to address
donor and patient safety concerns.
The NMDP is a leader in developing information
systems to support its extensive network of centers,
patients, and the public. In 1992, the NMDP intro-
duced its proprietary Search Tracking and Registry
(STAR) computer system that was designed to expe-
dite the process of matching potential donors with
patients and improving communication between the
NMDP Coordinating Center and its network of
centers. The STAR system has evolved over the past
15 years to include sophisticated software applications
that support the work performed at transplant centers,
donor centers, CB banks, and the NMDP repositories.
HapLogicSM, an enhancement to the search algo-
rithm, was implemented in 2006. HapLogic utilizesmathematic formulas developed by Mori et al. [16] to
predict a donor’s or cord blood unit’s (CBU) high-
resolution match with a patient, thus contributing to
a reduction in the number of donors or CBUs
requested for testing and to faster identification of a
donor or CBU for transplantation.
The NMDP maintains a public Web site
(www.marrow.org) to provide information to donors,
patients and their families, referring physicians, and
other interested persons from the public and medical
community.
Access to transplant for the diverse American pop-
ulation has been a major focus of the NMDP. Donor
recruitment campaigns targeted to specific racial and
ethnic groups have contributed to the racial and ethnic
diversity of the NMDP Registry, whereas educational
programs for referring physicians and third party
payors have increased access to transplant for patients
who otherwise may not have had this treatment option
available to them.
The Marrow Foundation, the official charitable
organization of the NMDP, was established in 1991.
Funds raised by The Marrow Foundation provide
financial support to help patients through their
transplant journey, add fully HLA typed donors to the
registry, and fund research. In 2007,TheMarrowFoun-
dation provided more than 4 million dollars to help
more than 1000 patients manage the cost of transplant.
The NMDP established the Office of Patient
Advocacy (OPA) in 1991 to assist patients and their
families through the process of searching for a donor
and transplantation. Today, professional case man-
agers help patients learn about transplantation, review
transplant statistics, prepare financial plans, and
understand insurance coverage. In 2007, OPA pro-
vided service to over 11,500 patients. In 2001, the
NMDP formally established a Donor Advocacy
Program. This program is designed to provide donors
with information about potential complications and
help if complications do occur, find answers to donor
insurance and financial questions, and overcome bar-
riers to donation.
The founders of the NMDP had the foresight to
require transplant centers to submit baseline and out-
comes data on all NMDP-facilitated transplants, thus
establishing a research database from which retrospec-
tive outcome analyses could be performed. In addition
to recipient outcomes, the NMDP also collected data
on donor outcomes. In 1992, the NMDP established a
research sample repository that stores blood samples
from recipients and their donors. The repository
now includes over 16,000 donor/recipient paired sam-
ples and is the cornerstone of the immunogenetics
research program.
In 2004, the NMDP expanded its research focus
from unrelated transplantation to include allogeneic
related and unrelated transplantation and autologous
NMDP Overview 7transplantation when it formed an affiliation with the
International Bone Marrow Transplant Registry to
create the Center for International Blood and Marrow
Transplant Research (CIBMTR).This research organi-
zation, with its 17 working committees, is responsible
for the design and implementation of retrospective re-
cipient and donor outcomes studies, immunogenetics
research, health services research, and prospective clin-
ical trials. In addition to its ownprospective clinical trials
program, the CIBMTR, together with the NMDP and
EMMES Corporation, serves as the data coordinating
center for the National Institutes of Health funded
Blood andMarrowTransplant Clinical Trials Network
(BMT CTN). In 2007, the CIBMTR and NMDP
published 59 articles in peer-reviewed journals.
TheNMDPhas grown into a large international or-
ganization providing patients with access to over 7 mil-
lion donors in the NMDP Registry and 10 million
donors worldwide. The NMDP continues to face chal-
lenges in terms of funding, minority recruitment, and
expansion. Nonetheless, the basic principles of donor
safety, concern for the patient, and advancement of the
field remain paramount. Over 30,000 patients have
benefited from this remarkable organization. The arti-
cles that follow outline the organization’s achievements
in pediatric and adult transplant outcomes, advances in
HLA typing, and donor activity and outcomes.
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